Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT041 in advanced digestive system cancers
NCT04404595Phase 2Active, not recruiting
- Sponsor
- CARsgen Therapeutics
- Start
- Oct 2020
- Primary completion
- Jun 2025
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of satricabtagene autoleucel in gastric cancer (GC), pancreatic cancer (PC), biliary tract cancer (BTC), sponsored by CARsgen Therapeutics. Started Oct 2020; status: active, not recruiting.
02
Drugs
satricabtagene autoleucel
03
Conditions
gastric cancer (GC)pancreatic cancer (PC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04404595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04404595.